Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021
Retrieved on:
Thursday, September 16, 2021
PD-L1, Immunotherapy, Thyroid cancer, 2021 Essex County Council election, Genetic counseling, European Society for Medical Oncology, Cholangiocarcinoma, Patient, TMB, ESMO, GTH, Sarcoma, Bethesda system, EPHA3, Genomics, Stromal cell, Disease, Trauma, Neoplasm, NASDAQ, Solution, Abstract (summary), KRAS, BSRTC, FNA, GLOBE, SMARCA2, Lung cancer, Cancer, Diagnosis, Research, SMARCA4, Oncology, Health, Congress, Medical imaging
The research adopted Genetrons proprietary technology such as the One-Step Seq Method, and core products such as Onco PanScanand its thyroid cancer full-cycle gene test.
Key Points:
- The research adopted Genetrons proprietary technology such as the One-Step Seq Method, and core products such as Onco PanScanand its thyroid cancer full-cycle gene test.
- These findings were from both multi-cancer studies and high-risk single cancer studies, which covered lung cancer, thyroid cancer, cholangiocarcinoma, and central nervous system cancers.
- Genetron Health's research findings provide new strategies for precise diagnosis and treatment of the Chinese population.
- For these patients, Genetron Health has developed a full-cycle gene test for thyroid cancer that is based on the One-Step Seq Method.